Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 5/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 3/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4249695 | 1.00 | HCAR2 (0.53) | HCAR2TSHRATMNAAAHPGD | |
| SCHEMBL4249688 | 1.00 | HCAR2 (0.53) | HCAR2TSHRATMNAAAHPGD | |
| SCHEMBL4247945 | 0.98 | HCAR2 (0.51) | HCAR2TSHRATMNAAAHPGD | |
| SCHEMBL4253657 | 0.98 | HCAR2 (0.51) | HCAR2TSHRATMNAAAHPGD | |
| SCHEMBL4247950 | 0.98 | HCAR2 (0.51) | HCAR2TSHRATMNAAAHPGD | |
| SCHEMBL4251457 | 0.93 | ATM (0.57) | HCAR2TSHRATMNAAAHPGD | |
| SCHEMBL4251461 | 0.93 | ATM (0.57) | HCAR2TSHRATMNAAAHPGD | |
| SCHEMBL4254653 | 0.93 | ATM (0.57) | HCAR2TSHRATMNAAAHPGD | |
| SCHEMBL4256586 | 0.85 | HCAR2 (0.47) | HCAR2TSHRATMHPGDNPSR1 | |
| SCHEMBL4253375 | 0.85 | HCAR2 (0.47) | HCAR2TSHRATMHPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2105431-A1 | Process for Producing Chromone Compound | Sumitomo Chemical Company, Limited (JP) | 2009-09-30 | — | — | EP | disclosed |
| EP-2105432-A1 | Process for Producing Chromone Compound | Sumitomo Chemical Company, Limited (JP) | 2009-09-30 | — | — | EP | disclosed |
| EP-1867626-A2 | Process for producing chromone compound | Sumitomo Chemical Company, Limited (JP) | 2007-12-19 | — | — | EP | disclosed |
| US-20060217565-A1 | Process for producing chromone compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-09-28 | — | — | US | disclosed |
| US-7094914-B2 | Process for producing chromone compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-08-22 | — | — | US | disclosed |
| US-20050085664-A1 | Process for producing chromone compound | SUMITOMO CHEMICAL COMPANY, LMITED (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1479667-A1 | PROCESS FOR PRODUCING CHROMONE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085664-A1 | Process for producing chromone compound | ENY2, CDY1; CDY1B, CDYL | HCAR2 354/4885TSHR 1710/4885ATM 1987/4885 |
| US-20060217565-A1 | Process for producing chromone compound | ENY2, CDY1; CDY1B, CDYL | HCAR2 354/4885TSHR 1710/4885ATM 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.